Representative Latta Proposes Bill to Ban New Abortion Drugs and Require In-Person Doctor Visits
This bill is currently sitting in the House Committee on Energy and Commerce. It is considered stalled because no action has been taken on it since January 2025. The bill will not move forward unless the committee decides to hold a hearing or a vote.
No action since January 2025
This bill’s path across every version that has carried it.
Reintroduced
Reintroduced from H.R. 427 (118th), which died when its Congress ended.
H.R. 427 (118th) →Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
This bill would dramatically restrict access to medication abortion (mifepristone) for pregnant individuals seeking to end a pregnancy. It bans mail-order and pharmacy dispensing, requiring in-person visits to a certified doctor at a clinic, medical office, or hospital. It also freezes the gestational limit at 70 days and prohibits any future loosening of these rules. For the roughly 500,000+ people per year who use medication abortion, this creates significant new barriers including travel, cost, and time burdens — especially in rural areas or states with few providers.
Referred to the House Committee on Energy and Commerce.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
The bill prohibits the approval of new abortion drugs by the HHS Secretary and prevents investigational use exemptions for drugs in research phases. For existing drugs, it bans pharmacy dispensing and mail-order delivery, requiring in-person administration by a certified healthcare practitioner.
The SAVE Moms and Babies Act of 2025 (H.R. 685), introduced by Rep. Bob Latta, would prohibit the approval of new abortion drugs and label changes to existing medications. It requires administration in an office setting and imposes strict reporting requirements on adverse effects.
Senator Cindy Hyde-Smith reintroduced the SAVE Moms and Babies Act to prevent the FDA from lifting regulations on abortion medication. The bill aims to block mail-order distribution and telemedicine prescriptions, while critics argue it ignores data showing serious complications are rare.
No votes recorded for this bill yet.
Document Type
Congressional Bill
Official Title
SAVE Moms and Babies Act of 2025
Analysis generated by AI. Always verify with official sources.